International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 31, Issue 4, April 2025 ijppr.humanjournals.com ISSN: 2349-7203

# Glucose Variability in Juvenile Diabetes Insights into Pathophysiology Clinical Implications and Therapeutic Strategies

**Anjali Chungkham[1], Darla Srinivasa Rao[2]*, Shagun Agarwal[3], Is-hak Salum[4]**

[1,4]Department of Medical Laboratory Technology, School of Allied Health Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India.

[3]Professor, Department of Physiotherapy, School of Allied Health Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India

Received: 2025-4-01 Revised: 2025-4-12 Accepted: 2025-4-20

**ABSTRACT**

Glucose variability (GV) has emerged as a critical determinant of metabolic control and long-term consequences of the disease, as it is juvenile diabetes commonly known as Type 1 Diabetes Mellitus (T1DM). GV differs from chronic hyperglycemia in that the blood glucose levels rise abruptly, increasing the risk of hypoglycemia, oxidative stress as well as endothelial damage. Numerous factors, including insulin therapy, food consumption, exercise, and mental stress, affect these variations. Insulin pumps and CGM systems have brought greater success in treating GV because they help doctors better manage blood sugar plus decrease the chance of dangerous hypoglycemic episodes. A complex strategy including pharmacological therapies, lifestyle changes, and real-time monitoring technology is required to achieve optimal glycemic stability despite breakthroughs in diabetes management. With the aim to reduce fluctuations and enhance patient outcomes, this review attempts to present a thorough examination of the mechanisms causing glucose variability in juvenile diabetes, its clinical implications, and the most recent developments in therapeutic methods.

**Keywords:** Glucose Variability, Juvenile Diabetes, Insulin Therapy, Oxidative Stress, Glycemic Control.

## 1. INTRODUCTION

Diabetes mellitus occurs when problems with insulin production or use cause the body to process sugar imbalances and disrupt metabolisms of carbohydrates, proteins and fats. The illness progression causes functional damage to blood vessels and organs which leads to major diabetic complications such as eye, nerve, kidney, heart, and skin injuries. Diabetes exists in many separate medical conditions with different features. Diabetes remains the major endocrine disorder while statistics show that 200 million people will have DM by 2010 and 300 million will develop it by 2025. In 1965 the World Health Organization initially developed diabetes diagnostic standards which later guides were updated by both WHO and NDDG in 1979 and then by WHO in 1980. WHO made minor updates to its recommendations in 1985. ADA published new guidelines for diabetes diagnosis in 1997 and WHO did the same in 1999. The two groups support the same diabetes control standards [1, 2].

### 1.1 Classification of diabetes

Type 1 DM occurs when the body needs no insulin and results from immune system damage. Before the new classification system took effect IDDM stood as the formal name for this condition. The fundamental part of this disorder destroys B-cells through autoimmunity while blood sugar issues appear when 90% of these cells disappear. Type 2 diabetes creates most diabetes cases across the world and this type accounts for between 90% to 95% of all diabetes cases. The illness builds up because of decreased insulin levels but showcases primary insulin resistance [3]. Approximately ninety percent of diabetes patients fit into type 1 or type 2 categories but this classification system does not work for other individuals. Clinicians normally identify diabetes types through patient symptoms at diagnosis while assessing patient age at diagnosis, obesity level, blood sugar levels, and insulin dependency for therapy. Identifying type 1 diabetes early is essential because it prevents ketoacidosis development and reduces death risk. Type 1 diabetes patients with diabetic ketoacidosis need urgent medical care because this condition shows up with specific neurologic symptoms [4]. Type 1 diabetes causes symptoms to develop rapidly unlike other forms of the disease. A diagnosis includes frequent urination, excessive thirst, eating more GER, unexplained weight decrease, extreme tiredness, stomach pains, constipation, blurry sight, and yeast infections. Patients with type 1 diabetes for a long time develop both tiny blood vessel and large artery problems [8]. Type 2 DM shows the same health problems but starts without obvious signs. People find out about their diabetes condition through difficulties it causes or when healthcare providers detect it by chance. Type 2 DM increases the risk of developing large vessel atherosclerosis along with the other risk factors for hypertension, high blood lipids and weight problems. Individuals with type 2 diabetes mostly pass away from heart diseases followed by total kidney breakdown. Research reveals place-based differences concerning how badly diabetes affects health and how it causes harm to people [9]. Medical staff detected diabetes by checking if fasted blood glucose was over 7mmol/L (126 mg/dL) or if blood glucose tested randomly was above 11.1mmol/L (200mg/dL) with accompanying signs of high blood sugar or results from a 2-hour glucose tolerance test. In 2009 the American Diabetes Association elevated HbA1C testing to confirm diabetes when results reached 6.5% or higher. Although organizations try to create a single type 1 diagnosis process the underlying reasons for the condition remain difficult to define. It is challenging to find out if adult diabetes patients have Type 1 or Type 2. Studies indicate that between 5% and 15% of adults with Type 2 diabetes should have been classified as type 1 diabetes since their blood test results showed islet autoantibodies. Proper diagnosis of this disease is essential to deliver the best possible care and prevent problems from happening. Being aware of diabetic ketoacidosis during the first diagnosis of Type 1 disease helps patients survive better. Scientists recognize two main types of adult diabetes by naming them latent autoimmune disease of adult (LADA) and ketosis-prone diabetes. The absence of clear LADA criteria and the connection between Type 1 diabetes and LADA patients has hindered researchers from recognizing LADA as a new diabetes type. [10, 11]

**Table 1: Summary about classifications of diabetes**

| Type | Description |
|---|---|
| Type 1(1a,1b) | Breakdown of ß-cells with minimal or no endogenous Ability to secrete insulin Autoimmune Idiopathic |
| Type 2 | Comprises varying conditions between insulin deficiency and both insulin secretion defects and insulin resistance issues |

## 2. Pathogenesis

The starting factors from outside contribute substantially to developing Type 1 Diabetes. Research on identical twins shows symptoms appear in about half these subjects with T1DM and never affect more than half of the pairs. The environmental triggers of T1DM are viruses such as rubella and coxsackievirus B plus enteroviruses, food proteins in cow's milk and cereal products. Researchers still need to understand how these elements contribute to T1DM development because these possible causes need identification. Special changes of these elements may help predict ways to stop or manage the condition [12].

### 2.1 Viruses and vaccinations

Epidemiological studies first showed that viruses start the process that leads to T1DM development. Children who were infected with rubella before birth develop T1DM at higher rates plus autoimmune thyroiditis. Viruses causing this infection were later detected in patient pancreases and surrounding body parts. Invading enteroviruses help establish T1DM during the initial body's immunological response. The development of T1DM and related genes correlates with specific changes found at the IFIH1 genetic location that produces MDA5. During virus infection of cells MDA5 sets off the innate immune response sensors in the cytoplasm of cells mainly from coxsackievirus B [13, 14]. People believed vaccines could lead to autoimmune disease development after vaccination including type 1 diabetes. Research shows genetic predisposition in siblings of T1DM patients may exist yet immunization of newborns holds no link to developing T1DM [15].

### 2.2 Diet and gut microbiota

People have different opinions about how diet affects the development of T1DM. Studies show that giving cow's milk to infants early increases their disease risk because their immune response is triggered waiting for milk insulin [16]. People with T1DM show distinct gut microbiota patterns compared to healthy individuals since they have lower levels of the Firmicutes group next to more Bacteroidetes microbes. More research needs to establish how changes in gut microbiota develop alongside changes in nutrition and lifestyle during early life which increases T1DM rates but may come from the condition itself. Research shows babies born through cesarean delivery develop a higher T1DM risk. The absence of normal vaginal microbiome contacts during childbirth alongside changes in newborn gut microbiota due to uneven colonization forms a potential disease process and suggests vaginal delivery benefits. The gut microbiota changes our immune system in different ways but we still need to discover more about this relationship to make progress in fighting and treating Type 1 diabetes [17, 18].

**International Journal of Pharmacy and Pharmaceutical Research (IJPPR)**
Volume 31, Issue 4, April 2025 **ijppr.humanjournals.com** ISSN: 2349-7203




**Figure 1: Showing pathogenesis of Type 1 diabetes**

### 2.3 Genetic factors

Patients who get Type 1 diabetes show no history of the condition in their family. Defense of Type 1 diabetes runs strongly within families when only 10% to 15% patients have family members affected by this condition. Close blood relatives of patients have increased lifetime odds of T1DM because 6% of genetically related children become sick whereas only 5% of siblings and half of identical twins develop diabetes while 0.4% of the population at large contract T1DM during their lifetimes. Multiple T1DM genetic risk areas of the genome have been detected from genome-wide association research and large-scale data analysis. The main T1DM genetic regions are located in the MHC area on chromosome 6 which is also known as HLA. The different forms of HLA genetic variants explain half of our risk for developing type 1 diabetes. Activating polymorphic insulin genes on chromosome 11 and inhibiting CTLA-4 genes on chromosome 2 take the second and third risk genes ranks since they together account for 15% of T1DM genetic factors. Many researchers found fewer genetic loci that add small amounts to the genetic risk of T1DM condition and other autoimmune diseases [19,20].

**Table 2: Display what causes Type 1 diabetes.**

| Factors | Examples |
|---|---|
| Genetic factors | HLA 2<br>Insulin-VNTR 3.<br>CTLA-4 |
| Environmental factors | Diet (cow's milk, cereals, omega-3 fatty acids, vitamin D)<br>Gut microbiota |
| Virus's infections | Rubella, Enteroviruses |

## 3. Treatment

The treatments for Type 1 diabetes do not rely on single methods rather than include insulin therapy, lifestyle changes, and routine monitoring, which are all part of the treatment.

Insulin treatment for type 1 DM starts easier because patients mainly appear with ketoacidosis. The amount of insulin needed during IV infusions to normalize anion gap and blood sugar from diabetic ketoacidosis helps predict the overall subcutaneous insulin requirements. People typically use those insulin treatments that combine two injections per day of premixed insulin with basic insulin boluses. Type 1 DM patients benefit from metformin when they are overweight alongside their condition yet further oral treatments offer no benefits [21]. Doctors mostly use insulin pumps to help patients with Type 1 diabetes mellitus. The DCCT restored interest in subcutaneous insulin infusion devices (CSII) because their ability to control blood sugar well reduced the risk of medical issues. Medication is inserted into the stomach area through a subcutaneous cannula for 24 hours during a continuous flow

International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 31, Issue 4, April 2025 ijppr.humanjournals.com ISSN: 2349-7203

while adjusting the amounts based on food intake. Under UK medical guidelines doctors must start CSII therapy only when patients have blood sugar levels above 69mmol/mol (8.5%). The high pump maintenance expenses plus other costs determine this result. Transformer-type insulin delivery systems help people with reduced neurologic function benefit from medical treatment especially when they cannot operate standard insulin pens [22]. Type 1 diabetics typically do not gain exercise benefits because they take more carbohydrates to avoid hypoglycemia during physical activities. Type 1 diabetics need to decrease their insulin intake or eat more carbohydrates to avoid hypoglycemia when participating in light to moderate exercise. At high-intensity exercise duration and immediately following them blood sugar levels rise sharply although this happens to everyone even without diabetes. Untreated Type 1 diabetes makes it impossible for insulin levels to rise normally during hyperglycemia which leads to larger and longer periods of high blood sugar in comparison. Active Type 1 diabetics experience less severe health problems and pass away less often than people who stay inactive. Diabetic people gain many health advantages from physical exercise yet face both medical threats and medical rewards. The hazards from physical activity rise higher for Type 1 diabetic patients, while Type 2 diabetics get more relief from their workouts. Type 1 diabetics should exercise because of their younger age group yet face greater physical benefits compared to Type 2 diabetics [23, 24]. In 2000 scientists created a new procedure for islet transplants without cortisol-based immunosuppression but patient outcomes improved at first and then dropped to 10% independence from insulin at 5 years. Since then islet transplantation continues as research for better methods with polymeric scaffolds and immune protection devices among others. Similar issues affect the development of stem cells as new β cell substitutes from their start point in research. The medical community hopes that insulated cells with immunoprotection systems will eventually lead to successful treatments. [25, 26] Because there is no treatment for type 1 diabetes patients need to check their blood sugar levels through skin punctures. The results of these tests are used to determine how much insulin they need. Patients experience finger prick testing as inconvenient and painful operations. Our body data at a specific moment tells us little about how our blood glucose levels change over time through day and night. CGM systems take repeated readings of blood glucose levels without being fully continuous. CGM technology adds a very slim injection needle that goes beneath abdominal fat for placement. The needle tip holds a device that takes glucose measurements from fat tissue near the insertion site. These tests reveal if CGM technology lets patients maintain their diabetes treatment results and improve their daily life quality [27]. Most new Type 1 diabetes patients show their symptoms before age 18 without obesity issues. Close relatives of diabetic patients develop the condition with ten times greater frequency and scientists have linked specific immune system markers with this disease. The analysis of identical twins shows that people with inherited risk for diabetes need to encounter both virus exposure and genetic risk for this disease to develop. The autoimmune process starts after pancreatic B cell damage caused by viruses reveals antigens that trigger autoimmunity. After B cell destruction reaches more than 90% patients develop an overt diabetic condition. The absence of insulin creates long term memory deficits that produce learning and memory impairment. Type 2 diabetes produces two main pathologic characteristics which together generate its development: insulin resistance and impaired insulin secretion. These patients are generally obese because B-cell function reduces with age which leads to their diagnosis during adulthood as the disease progression becomes more common. The combination of insulin resistance results in the formation of Aβ plaques together with tau protein hyperphosphorylation. Hyperinsulinemia results when insulin and Aβ interact with insulin degrading enzyme, leading to Aβ buildup and plaque creation. The decreased insulin receptor signaling activates GSK-3β through dephosphorylation, leading to tau protein hyperphosphorylation [28, 29]. Childcare providers need to recognize that families with children who have special needs typically experience reduced quality of life especially when parents of children with T1DM have witnessed their child's T1DB unconscious state or seizure activity which generates serious concerns about the child's functionality and welfare and fear within these children from parental anxiety [30].




**Figure 2: Showing the treatments of Type 1 diabetes**

## 4. Review of literature

Type 1 diabetes mellitus affects only a small percentage of people across the globe even though it starts causing health problems during the first years of childhood. Damage to the immune system destroys beta cells inside the pancreas to cause the development of T1DM. The smaller group of patients making up less than 10% develop Type 1B which does not involve immune system damage and scientists say they acquire this condition by unknown methods. Type 1 diabetes displays significant variation in terms of its prevalence and incidence across worldwide populations. The European nations of Finland and Sardinia stand out for having one of the world's highest numbers of Type 1 diabetes patients with over 60 new occurrences each year in every 100,000 people. China and India report the lowest rates of the disorder with Venezuela matching these numbers through annual records of less than 0.1 cases per 100,000 people. Type 1 diabetes studies reveal mysteries because national border neighbors in Europe and North America show big variations in new case rates. Despite being only 120 kilometers apart Estonia records less than one-third of Finland's diabetes cases. Diabetes Type 1 cases continued to rise globally during several decades. Studies revealed Finland experienced 2.4% growth, Germany experienced 2.6% growth, and Norway had a 3.3% surge annually. The worldwide increase in Type 1 diabetes shows variations among different countries yet Sweden recently reported consistent incidence rates. The present growth trajectory of incidence rates will result in worldwide Type 1 diabetes numbers witnessing a doubling effect by the next ten years. Research data reveals that children younger than five years old experience the greatest increase in new cases of Type 1 diabetes in Europe. Scientists remain unaware of the mechanics behind geographical variations in Type 1 diabetes prevalence and rising incidence patterns of this condition although environmental factors received the most credit for these occurrences. Type 1 diabetes patterns do not increase simply because of genetic changes or women with diabetes having multiple children. The requirement of genetic predisposition for type 1 diabetes development shows declining influence as a precondition in present times. [5,6,7].Type 1 diabetes shows its highest increases in incidence among children under the age of 15 years old who are also below 5 years old. Genetic data fail to clarify these increases as such changes cannot account for them which leads to the conclusion that environmental effects together with behavioral influences are responsible factors. During the early and adult stages different environmental conditions can activate the development of Type 1 diabetes. These include dietary practices in early and present life as well as vitamin D availability and exposure to viral agents (enteroviruses) known for damaging pancreatic islet tissues. Moreover, decreases in gut microbiome diversity seem to contribute to the disease risk. A positive relationship exists between obesity and Type 1 diabetes development because ß-cells stress appears to function as an underlying cause. The impact of environmental triggers shows in type 1 diabetes rates between people from the same genetic background who live separate lives and exists alongside genetic research about Type 1 diabetes. Scientists conduct research to determine how different disease factors work at distinct stages of Type 1 diabetes and identify which sites unrelated to risk affect disease progression after immune activation begins. According to some data, the observed prevalence may be decreasing in adults or possibly leveling off across all age groups; global registry data will eventually show whether or not this pattern is accurate [31,32,33]. The occurrence of Type 1 diabetes differs among different parts of the country. Children born in the spring through the northern regions showed greater risk for developing the condition than infants born at other times of year. Diagnoses are most common in youngsters between the ages of 10 and 14. Profiling Type 1 diabetes in adults proves challenging because Type 2 diabetes cases outnumber Type 1 episodes while diagnosis standards remain insufficient. The vast majority of Type 1 diabetics are adults [34, 35].

### 4.1 Type 1 diabetes poses greater risks to life and health.

Research struggles to predict the total impact of Type 1 diabetes due to its difficulty distinguishing between Types 1 and 2 diabetes. Based on recent research the total yearly spending on Type 1 diabetes management in the United States ranges between 14.4 billion and 14.9 billion. For patients with Type 1 diabetes, attaining normoglycemia is a crucial therapeutic objective, particularly to prevent complications, regardless of the associated financial implications [36].

### 4.2 Type 1 diabetes-related complications

Type 1 and 2 diabetes complications take two forms: large blood vessel diseases and small blood vessel diseases. Diabetic patients of Type 1 now reaching longer life expectancy increase their chances of heart problems. People with Type 1 diabetes face ten times greater risk of heart problems, including heart attack, stroke, chest pain, and coronary artery treatment needs, compared to non-diabetic people their age. The Pittsburgh Epidemiology of Diabetes Complications research discovered adult patients with Type 1 diabetes under 40 get one cardiovascular event per year, while those above 55 develop three times more events. The EDIC study showed during its research that blood sugar control through intensified treatment reduced cardiovascular risks among Type 1 diabetes patients by 42% compared to regular medical care. After a heart attack patients with type 1 diabetes see worse results than non-diabetic patients while expressing cardiac protein antibodies. These patients differ from persons with type 2 diabetes who do not show these antibodies. The risk for microvascular complications, including retinopathy, nephropathy, and neuropathy, reduces with intensive insulin therapy. [37, 38]

### 4.3 Prevention

The earliest immune-based medicines to reverse Type 1 diabetes, which included cyclosporine, were attempted nearly three decades ago. Modern medicine has made significant improvements through advanced metabolic tools and better illness understanding with addition of immunologic markers. Magnified type 1 diabetes studies happen across multiple leading medical organization networks such as NIH Trial Net and Immune Tolerance Network who conduct precise experimental tests and scientific practices. Finally, while contentious, treatment strategies have definitely profited from research in animal models of Type 1 diabetes, particularly the NOD [39]. Type 1 diabetes has become a condition we can predict while trials across the country study ways to stop or slow its development. Research on Type 1 diabetes primary prevention mostly studies diet changes for infants with a genetic risk but without islet autoantibodies. Researchers in Finland selected newborns who had a Type 1 diabetes relative and put them randomly into either hydrolyzed baby formula or regular formula when breast milk was unavailable for 6 to 8 months. Children who were given hydrolyzed formula had less chance of developing two or more islet autoantibodies than those taking regular formula at baseline (unadjusted hazard ratio of 0.52). After three years of follow-up, a different trial that eliminated bovine insulin from newborn formula found that infants who received regular cow's milk formula showed less progression toward the production of one islet autoantibody [40, 41]. Research with this group seeks to slow down the start of Type 1 diabetes in subjects who show high islet autoantibody reactions yet have normal blood glucose levels. Research required participants who took oral insulin, who had Type 1 diabetes in their first-degree relative, and demonstrated two islet autoantibodies with an insulin antibody present. The oral insulin treatment did not slow down the progression to diabetes but further study results showed that patients with high insulin antibody levels received benefits with treatment and their diabetes probably was delayed 5 years. Other agents used for secondary prevention, nicotinamide and intranasal insulin, have not been shown to delay or prevent diabetes onset. [42, 43]

### 4.4 Considerations for oral health and treatment

Oral health professionals should recognize that young people with Type 1 Diabetes face frequent hypoglycemic or hyperglycemic events from their blood sugar control problems. The oral health treatment plan requires full health records from all involved parties plus knowledge about the patient's blood glucose management process. Because dental caries is a multifactorial disease, salivary counts of Streptococcus mutans (S. mutans) and Lactobacilli are higher in patients with active caries, whether diabetic or not, and while some factors in T1DM may increase the risk of dental caries while others may reduce it, there is no consistency in caries prevalence and cariogenic bacteria levels between children with or without diabetes [44]. The presence of cariogenic bacteria S. mutans and L. casei may grow more often in diabetes patients compared to non-diabetic children, specifically among those who cannot manage their disease well. Research discovered neither variations in S. mutans and L. casei numbers nor dental cavity rates between diabetic and nondiabetic children, along with confirming the connection between tooth decay and saliva blood sugar levels. Additionally, it has been noted that children with poorly controlled diabetes have a larger frequency of dental caries in their permanent teeth than in their deciduous teeth, despite the fact that the latter had a lower prevalence than the healthy controls [45, 46]. A number of factors could be responsible for these inconsistent and potentially contradictory findings, including a correlation between changes in oral microbiota and dietary practices, decreased unstimulated and stimulated salivary secretion in children with diabetes, increased salivary pH and buffering capacity, increased saliva viscosity, increased levels of carbohydrates, glucose, and total protein, higher levels of IgA and IgG antibodies, and lower levels of antimicrobial proteins like lactoferrin and lysozyme in diabetic patients [47]. Scientists have studied immune system control methods as the main Type 1 diabetes cure strategy since 30 years ago. Trials using cyclosporine, an immunosuppressant used to prevent T-cell activation, were the first steps in this strategy. Patients' insulin needs decreased during active therapy, despite cyclosporine's inability to produce a long-lasting illness remission. People thought immune regulation may work to treat Type 1 diabetes. Later studies examined various alternative approaches for prevention within both initial stages and after the disease develops. Research has mainly tried to modify immune system responses against T cells, B cells and cytokines while studying tolerance to antigens. Dietary methods have also been used in certain primary prevention trials [48]. Different versions of the glutamate decarboxylase (GAD) protein have been employed in antigen-based experiments; the findings have been variable but generally unfavorable. The main goal of the Diabetes Prevention Trial Type 1 was to test the ability of oral and parenteral insulin to delay or stop Type 1 diabetes developing in people with autoantibodies. Subgroup testing revealed oral insulin would help people with high levels of insulin auto-antibodies but failed to block Type 1 diabetes development. The Type 1 Diabetes Trial Net Network tried low-dose oral insulin treatment on a new group of patients who showed similar insulin autoantibody levels before performing this test. This second research also delivered no positive results. In a further research project scientists determined that administering insulin through the nose failed to produce any study outcomes [49, 50].

## 5. Conclusion

Type 1 diabetes, which primarily affects children and young people, continues to be a significant global health challenge for medical professionals. Type 1 diabetes cannot be completely cured by improved insulin therapy and blood sugar monitoring. Research teams continue to work on developing treatments using immune system methods and regenerating beta cells plus stem cells. Early detection of the condition along with medical training and advanced monitoring tools enhances how people with diabetes can control their disease better and enjoy better lives. Experts need additional research to create permanent fixes that can stop or reverse the condition. A comprehensive effort through healthcare teams works with research experts and officials to handle the rising Type 1 diabetes patient population and enhance treatment results. Keeping blood glucose under strict management protects from health problems. Tight blood glucose control raises the chance of developing dangerous hypoglycemic episodes which prove more harmful than high blood glucose levels. There are many challenges in the successful treatment of Type-I DM because of personal economic costs incurred in diabetes therapy. By following a healthy lifestyle, getting regular checkups, and taking proper medication we can observe a healthy and long life. But the result shouldn't give exact result in this type of test. The test will further continue with PPBS (Postprandial Blood sugar) and HbAlc (hemoglobin A1c) after that test gives appropriate results for the patients.

## 6. REFERENCES

1. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197.
2. World Health Organization Consultation. Definition, *Diagnosis and Classification of Diabetes Mellitus and its Complications, Part 1: Diagnosis and classification of Diabetes Mellitus. Report of a WHO Consultation*. Geneva: World Health Organization, 1999.
3. American Diabetes Association (2008). Economic costs of diabetes in the U.S. in 2007. Diabetes Care 31: 596–615. American Diabetes Association (2010a). Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 33: S62–S69.Smolyar AE, Hamrah P (2011). Bilateral posterior ischemic optic neuropathy in a patient with severe diabetic ketoacidosis. Case Rep Ophthalmol 2: 91–94
4. Paschou SA, Petsiou A, Chatzigianni K, Tsatsoulis A & Papadopoulos GK. Type 1 diabetes as an autoimmune disease: the evidence. *Diabetologia* 2014 **57** 1500–1501. (https://doi.org/10.1007/ s00125-014-3229-5)
5. Gillespie KM, Bain SC, Barnett AH, et al. The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. Lancet. 2004; 364:1699–700. [PubMed: 15530631]
6. Steck AK, Armstrong TK, Babu SR, Eisenbarth GS. Stepwise or linear decrease in penetrance of type 1 diabetes with lower-risk HLA genotypes over the past 40 years. Diabetes. 2011; 60:1045– 49. [PubMed: 21307077]
7. Kumar PJ, Clark M. Textbook of Clinical Medicine. Pub: Saunders (London), pp 1099-1121, 2002
8. Sekikawa A, Tominaga M, Takahashi K, et al. Prevalence of diabetes and impaired glucose tolerance in Funagata area in Japan. Diabetes Care 1993; 16: 57-574.
9. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012; 35(suppl 1):64–71.
10. Usher-Smith JA, Thompson MJ, Sharp SJ, Walter FM. Factors associated with the presence of diabetic ketoacidosis at diagnosis of diabetes in children and young adults: a systematic review. BMJ. 2011; 343:4092.
11. Beyan H, Riese H, Hawa MI, Beretta G, Davidson HW, Hutton JC, Burger H, Schlosser M, Snieder H, Boehm BO, *et al*. Glycotoxin and autoantibodies are additive environmentally determined predictors of type 1 diabetes: a twin and population study. *Diabetes* 2012 **61** 1192–1198. (https://doi.org/10.2337/db11-0971)
12. Hober D & Sauter P. Pathogenesis of type 1 diabetes mellitus: interplay between enterovirus and host. *Nature Reviews Endocrinology* 2010 **6** 279–289. (https://doi.org/10.1038/nrendo.2010.27)
13. Hober D & Sauter P. Pathogenesis of type 1 diabetes mellitus: interplay between enterovirus and host. *Nature Reviews Endocrinology* 2010 **6** 279–289. (https://doi.org/10.1038/nrendo.2010.27)
14. Yoon JW, Austin M, Onodera T & Notkins AL. Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. *New England Journal of Medicine* 1979 **300** 1173. (https://doi.org/10.1056/ NEJM197905243002102)
15. Hviid A, Stellfeld M, Wohlfahrt J & Melbye M. Childhood vaccination and type 1 diabetes. *New England Journal of Medicine* 2004 **350** 1398. (https://doi.org/10.1056/NEJMoa032665)
16. Virtanen SM, Saukkonen T, Savilahti E, Ylönen K, Räsänen L, Aro A, Knip M, Tuomilehto J & Akerblom HK. Diet, cow's milk protein antibodies and the risk of IDDM in Finnish children. Childhood Diabetes in Finland Study Group. *Diabetologia* 1994 **37** 381.
17. Beyan H, Wen L & Leslie RD. Guts, germs, and meals: the origin of type 1 diabetes. *Current Diabetes Reports* 2012 **12** 456462.(https://doi.org/10.1007/s11892012-0298-z)
18. Hu C, Wong FS & Wen L. Type 1 diabetes and gut microbiota: friend or foe? *Pharmacological Research* 2015 **98** 9–15. (https://doi.org/10.1016/j.phrs.2015.02.006)
19. Redondo MJ, Rewers M, Yu L, Garg S, Pilcher CC, Elliott RB & Eisenbarth GS. Genetic determination of islet cell autoimmunity in monozygotic twin, dizygotic twin, and non-twin siblings of patients with type 1 diabetes: prospective twin study. *BMJ* 1999 **318** 698. (https://doi.org/10.1136/bmj.318.7185.698)
20. Aly TA, Ide A, Jahromi MM, Barker JM, Fernando MS, Babu SR, Yu L, Miao D, Erlich HA, Fain PR, *et al*. Extreme genetic risk for type 1A diabetes. *PNAS* 2006 **103** 14074. (https://doi.org/10.1073/ pnas.0606349103)
21. DCCT Research Group (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329: 977–986.

22. NICE (2008). Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus: Review of technology appraisal guidance 57 ,http://www.nice.org.uk/ nicemedia/live/12014/41300/41300.pdf (accessed November 16, 2010).
23. Calles J, Cunningham JJ, Nelson L, et al. Glucose turnover during prolonged intensive exercise. Diabetes 1983; 32: 734-738.
24. Moy CS, Songer TJ, LaPorte RE, et al. Insulindependent diabetes mellitus, physical activity and death. Am J Epidemiol 1993; 137: 74-81
25. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes. 2005; 54:2060–69. [PubMed: 15983207]
26. Gibly RF, Graham JG, Luo X, Lowe WL Jr, Hering BJ, Shea LD. Advancing islet transplantation: from engraftment to the immune response. Diabetologia. 2011; 54:2494–505. [PubMed: 21830149]
27. Chase HP, Kim LM, Owen SL, MacKenzie TA, Klingensmith G, Murtfeldt R, et al. Continuous subcutaneous glucose monitoring in children with type 1 diabetes. Pediatrics 2001;107(2):222-6. [DOI] [PubMed] [Google Scholar]
28. Rang, H.P., Dale M.M., Pharmacology, Sixth Edition, Churchill Livingstone. "The Endocrine Pancreas and Control of Blood Glucose, 2008, Page No. 397-409.
29. Sims-Robinson, C., Kim, B., Rosko, A., How does diabetes accelerate Alzheimer disease pathology? *Nat Rev Neurol*; **6(10):** 551-559 (2010)
30. Herbert LJ, Clary L, Owen V, Monaghan M, Alvarez V, Streisand R. Relations among school/daycare functioning, fear of hypoglycaemia and quality of life in parents of young children with type 1 diabetes. J Clin Nurs 24: 1199-209, 2015.
31. Chobot A, Polanska J, Brandt A, et al. Updated 24-year trend of type 1 diabetes incidence in children in Poland reveals a sinusoidal pattern and sustained increase. Diabet Med 2017; 34: 1252– 58. [PubMed: 28257151]
32. Inshaw JRJ, Walker NM, Wallace C, Bottolo L, Todd JA. The chromosome 6q22.33 region is associated with age at diagnosis of type 1 diabetes and disease risk in those diagnosed under 5 years of age. Diabetologia 2018; 61: 147–57. [PubMed: 28983737]
33. Diaz-Valencia PA, Bougnères P, Valleron AJ. Global epidemiology of type 1 diabetes in young adults and adults: a systematic review. BMC Public Health 2015; 15: 255. [PubMed: 25849566]
34. Thomas NJM, Jones S, Weedon M, Hattersley A, Oram R. Classifying diabetes by type 1 genetic risk shows autoimmune diabetes cases are evenly distributed above and below 30 years of age. Diabetologia 2016; 59 (suppl 1): S135.
35. Chiang JL, Kirkman MS, Laffel LM, Peters AL. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care 2014; 37: 2034–54. [PubMed: 24935775]
36. Tao B, Pietropaolo M, Atkinson M, Schatz D, Taylor D. Estimating the cost of type 1 diabetes in the US: a propensity score matching method. PLoS One. 2010;5:11501.
37. Melendez-Ramirez LY, Richards RJ, Cefalu WT. Complications of type 1 diabetes. Endocrinol Metab Clin North Am. 2010; 39:625–40. [PubMed: 20723824]
38. Gottumukkala RV, Lv H, Cornivelli L, et al. Myocardial infarction triggers chronic cardiac autoimmunity in type 1 diabetes. Sci Transl Med. 2012; 4:138ra80.
39. van Belle TL, Coppieters KT, von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev. 2011; 91:79–118. [PubMed: 21248163]
40. Knip M, Virtanen SM, Seppä K, et al. Finnish TRIGR Study Group. Dietary intervention in infancy and later signs of beta-cell autoimmunity. N Engl J Med. 2010; 363:1900–8. [PubMed: 21067382]
41. Vaarala O, Ilonen J, Ruohtula T, et al. Removal of bovine insulin from cow's milk formula and early initiation of beta-cell autoimmunity in the FINDIA pilot study. Arch Pediatr Adolesc Med. 2012; 166:608–14. [PubMed: 22393174]
42. Gale EA. Dying of diabetes. Lancet. 2006; 368:1626–28. [PubMed: 17098062]
43. Beran D, Yudkin JS, de Courten M. Access to care for patients with insulin-requiring diabetes in developing countries: case studies of Mozambique and Zambia. Diabetes Care. 2005; 28:2136– 40. [PubMed: 16123479]
44. Siudikiene JV, Machiulskiene B, Nyvad J, Tenovuo J, Nedzelskiene I. (2006) Dental caries and salivary status in children with type 1 diabetes mellitus, related to the metabolic control of the disease. Eur J Oral Sci 114: 8-14, 2006
45. Lal SB, Cheng S. Kaplan, Softness B, Greenberg E, Goland RS, Lalla E, Lamster IB. Gingival bleeding in 6- to 13-year-old children with diabetes mellitus. PediatrDent 29: 426-30, 2007.
46. Orbak RS, Simsek S, Orbak Z, Kavrut F, Colak M (2008) The influence of type-1 diabetes mellitus on dentition and oral health in children and adolescents. Yonsei Med J 49: 357-65, 2008.
47. Zalewska A, Knaś M, Kuźmiuk A, Waszkiewicz N, Niczyporuk M, Waszkiel D, Zwierz K. Salivary innate defense system in type 1 diabetes mellitus in children with mixed and permanent dentition. Acta Odontol Scand 71: 1493-500, 2013.
48. Writing Group for the TRIGR Study Group. Effect of hydrolyzed infant formula vs conventional formula on risk of type 1 diabetes: the TRIGR randomized clinical trial. JAMA 2018; 319:38–48. [PubMed: 29297078]
49. Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group. Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes: a randomized clinical trial. JAMA 2017; 318: 1891–902. [PubMed:29164254]
50. Näntö-Salonen K, Kupila A, Simell S, et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008; 372: 1746–55. [PubMed: 18814906]

| |
|---|
| How to cite this article:<br>Darla Srinivasa Rao et al. Ijppr.Human, 2025; Vol. 31 (4): 1-9. |
| Conflict of Interest Statement: All authors have nothing else to disclose. |
| This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |